<DOC>
	<DOCNO>NCT00262314</DOCNO>
	<brief_summary>The overall objective study collect data relevant tolerability Novantrone® therapy patient multiple sclerosis ( MS ) use dose monitoring recommendation specify package insert .</brief_summary>
	<brief_title>Prospective , Open-label Tolerability Safety Monitoring Study Novantrone Selected Cohort Multiple Sclerosis Patients</brief_title>
	<detailed_description>This phase IV , multicenter , prospective , open-label tolerability safety monitoring study enroll select cohort 500 multiple sclerosis patient receive commercially available Novantrone® . The patient assess every 3 month treatment follow annual assessment total five ( 5 ) year . The select cohort MS patient enrol secondary ( chronic ) progressive , progressive relapsing , worsen relapsing-remitting disease ( i.e. , patient whose neurological status significantly abnormal relapse ) . The overall objective study collect data relevant tolerability Novantrone® therapy patient multiple sclerosis ( MS ) use dose monitoring recommendation specify package insert .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>To eligible inclusion study , subject must fulfill follow criterion : Platelet count &gt; 100,000 cells/µL Granulocyte count &gt; 2000 cells/µL Age 1865 year Negative pregnancy test female patient biologically capable become pregnant , even take birth control For patient reproductive age , agreement practice effective contraception throughout study 6 month follow last administration Novantrone® Signed Inform Consent . To eligible inclusion study subject must meet following criterion : Presence cardiac risk factor : History congestive heart failure LVEF &lt; 50 % determine echocardiography MUGA Previous treatment Novantrone® , anthracenediones , anthracyclines Prior mediastinal radiotherapy total lymphoidal irradiation AST , ALT , bilirubin &gt; 2x upper limit normal Severe untreated infection ( include current urinary tract infection ) Nursing pregnant woman )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>